NCT01695941 2026-04-13Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin LymphomaNational Cancer Institute (NCI)Phase 1 Active not recruiting24 enrolled